Welcome to our dedicated page for Zhibao Technology news (Ticker: $ZBAO), a resource for investors and traders seeking the latest updates and insights on Zhibao Technology stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zhibao Technology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zhibao Technology's position in the market.
Zhibao Technology Inc. (Nasdaq: ZBAO), a leading InsurTech company in China, announced the issuance of an additional 23,765 Class A ordinary shares. This issuance resulted from a partial exercise of the underwriters' over-allotment option in connection with its initial public offering (IPO). The shares were priced at $4.00 each, generating additional gross proceeds of $95,060. Including the over-allotment, the total gross proceeds from the IPO amounted to $6,095,060, excluding offering expenses and underwriting discounts. EF Hutton served as the sole book-running manager for the offering. The SEC declared the registration statement effective on March 29, 2024, and the final prospectus was filed on April 2, 2024.